RT Journal Article
SR Electronic
T1 Investigating the Relationship Between Rare Genetic Variants and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.02.24303632
DO 10.1101/2024.03.02.24303632
A1 Wattacheril, Julia
A1 Kleinstein, Sarah E.
A1 Shea, Patrick R.
A1 Wilson, Laura A.
A1 Subramanian, G. Mani
A1 Myers, Robert P.
A1 Lefkowitch, Jay
A1 Behling, Cynthia
A1 Xanthakos, Stavra A.
A1 Goldstein, David B.
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/03/04/2024.03.02.24303632.abstract
AB Background and Aims Nonalcoholic Fatty Liver Disease (NAFLD) is a complex human disease. Common genetic variation in the patatin-like phospholipase domain containing 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) genes have been associated with an increased risk of developing NAFLD, nonalcoholic steatohepatitis (NASH), and fibrosis in adults. The role of rare genetic variants in the development and progression of NAFLD in children is not well known. We aimed to explore the role of rare genetic variants in pediatric patients with advanced fibrosis.Methods Whole exome sequencing data was generated for 229 pediatric patients diagnosed with NAFLD recruited from the NASH Clinical Research Network (NASH CRN). Case-control single variant and gene-based collapsing analyses were used to test for rare variants that were enriched or depleted within the pediatric NAFLD cohort specifically for advanced fibrosis (cases) versus those without fibrosis (controls) or six other histologic characteristics. Exome data from non-NAFLD population controls were also used for additional analyses. All results were adjusted for multiple testing using a Bonferroni correction.Results No genome-wide significant associations were found between rare variation and presence of advanced fibrosis or NASH, nor the severity of steatosis, inflammation, or hepatocellular ballooning. Significantly, no enrichment of rare variants in PNPLA3 or TM6SF2 was observed across phenotypes.Conclusion In a cohort of children with histologically proven NAFLD, no genome-wide significant associations were found between rare genetic variation and advanced fibrosis or six other histologic features. Of particular interest was the lack of association with genes of interest in adults: PNPLA3 and TM6SF2, though limitations in sample size may reduce the ability to detect associations, particularly with rare variation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by: The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grants U01DK061713, U01DK061718, U01DK061728, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U24DK061730). Additional support is received from the National Center for Advancing Translational Sciences (NCATS) (grants UL1TR000077, UL1TR000150, UL1TR000424, UL1TR000006, UL1TR000448, UL1TR000040, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000454). This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute. Gilead Sciences, Inc provided funding for DNA sequencing.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional Review Board of Baylor College of Medicine gave ethical approval for this work The institutional Review Board of Cincinnati Childrens Hospital Medical Center gave ethical approval for this work The institutional Review Board of Emory University gave ethical approval for this work The institutional Review Board of Indiana University School of Medicine and Riley Hospital for Children gave ethical approval for this work The institutional Review Board of Northwestern University gave ethical approval for this work The institutional Review Board of Saint Louis University gave ethical approval for this work The institutional Review Board of University of California San Diego gave ethical approval for this work The institutional Review Board of University of California San Francisco gave ethical approval for this work The institutional Review Board of University of Washington gave ethical approval for this work The institutional Review Board of Johns Hopkins University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.